{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:43:53Z","timestamp":1787251433547,"version":"build-2736575974"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":99,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Basic Clin Pharmacol Toxicol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1111\/bcpt.12414","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T07:27:01Z","timestamp":1429774021000},"page":"306-315","source":"Crossref","is-referenced-by-count":20,"title":["Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir"],"prefix":"10.1111","volume":"117","author":[{"given":"Paolo","family":"Fagone","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mangano","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Quattrocchi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa","family":"Mammana","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.G.","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Britt","family":"Zocca","sequence":"additional","affiliation":[{"name":"OncoNox; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"He","sequence":"additional","affiliation":[{"name":"Center for Molecular Innovation; The Feinstein Institute for Medical Research; Manhasset NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Al-Abed","sequence":"additional","affiliation":[{"name":"Center for Molecular Innovation; The Feinstein Institute for Medical Research; Manhasset NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Catania; Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,25]]},"reference":[{"key":"10.1111\/bcpt.12414-BIB0001|bcpt12414-cit-0001","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/bcpt.12414-BIB0002|bcpt12414-cit-0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","article-title":"Anti-HIV drugs for cancer therapeutics: back to the future?","volume":"10","author":"Chow","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1111\/bcpt.12414-BIB0003|bcpt12414-cit-0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.imlet.2007.06.003","article-title":"Immunomodulatory effect of two HIV protease inhibitors, saquinavir and ritonavir, on lymphocytes from healthy seronegative individuals","volume":"111","author":"Delmonte","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1111\/bcpt.12414-BIB0004|bcpt12414-cit-0004","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2009.03.022","article-title":"HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages","volume":"78","author":"Chen","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/bcpt.12414-BIB0005|bcpt12414-cit-0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.dld.2006.01.020","article-title":"Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review","volume":"38","author":"Bruno","year":"2006","journal-title":"Dig Liver Dis"},{"key":"10.1111\/bcpt.12414-BIB0006|bcpt12414-cit-0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh013","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"53","author":"Calza","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/bcpt.12414-BIB0007|bcpt12414-cit-0007","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1086\/382531","article-title":"Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir ritonavir","volume":"38","author":"Mart\u00ednez","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/bcpt.12414-BIB0008|bcpt12414-cit-0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/qjmed\/hcg145","article-title":"Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?","volume":"96","author":"Nolan","year":"2003","journal-title":"QJM"},{"issue":"3","key":"10.1111\/bcpt.12414-BIB0009|bcpt12414-cit-0009","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI200316261","article-title":"HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages","volume":"111","author":"Dressman","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1111\/bcpt.12414-BIB0010|bcpt12414-cit-0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/1568009033481750","article-title":"Nitric oxide releasing non steroidal anti-inflammatory drugs: a new generation of anti-tumoral molecules","volume":"3","author":"Lavagna","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1111\/bcpt.12414-BIB0011|bcpt12414-cit-0011","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.antiviral.2011.07.001","article-title":"The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in\u00a0vitro indistinguishable from those of the parental compound saquinavir","volume":"91","author":"Canducci","year":"2001","journal-title":"Antiviral Res"},{"key":"10.1111\/bcpt.12414-BIB0012|bcpt12414-cit-0012","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1535-7163.MCT-08-0998","article-title":"The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt","volume":"8","author":"Maksimovic-Ivanic","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/bcpt.12414-BIB0013|bcpt12414-cit-0013","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1593\/neo.10856","article-title":"Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells","volume":"12","author":"Rothweiler","year":"2010","journal-title":"Neoplasia"},{"key":"10.1111\/bcpt.12414-BIB0014|bcpt12414-cit-0014","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4161\/cc.10.3.14727","article-title":"In vitro and in\u00a0vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells","volume":"10","author":"Donia","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1111\/bcpt.12414-BIB0015|bcpt12414-cit-0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/jcp.22513","article-title":"Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells","volume":"226","author":"Mijatovic","year":"2011","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1111\/bcpt.12414-BIB0016|bcpt12414-cit-0016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3892\/or.2012.1840","article-title":"Giovanni Lombardo GA, Maksimovic-Ivanic D, Mijatovic S, Zocca MB, Perciavalle V, Stosic-Grujicic S, Nicoletti F. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in\u00a0vitro and in\u00a0vivo tumor formation of A375 human melanoma cells","volume":"28","author":"Donia","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1111\/bcpt.12414-BIB0017|bcpt12414-cit-0017","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.4161\/cc.11.6.19611","article-title":"Saquinavir-NO targeted S6 protein mediates sensitivity of androgen dependent prostate cancer cells to TRAIL","volume":"11","author":"Mojic","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1111\/bcpt.12414-BIB0018|bcpt12414-cit-0018","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2013.03.010","article-title":"Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis","volume":"259","author":"Petkovic","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1111\/bcpt.12414-BIB0019|bcpt12414-cit-0019","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bcpt.12268","article-title":"Saquinavir-NO Inhibits IL-6 Production in Macrophages","volume":"115","author":"Momcilovic","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/bcpt.12414-BIB0020|bcpt12414-cit-0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2249.1997.4091423.x","article-title":"Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate","volume":"110","author":"Nicoletti","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/bcpt.12414-BIB0021|bcpt12414-cit-0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.1997.03540260059037","article-title":"HIV-1 protease inhibitors. A review for clinicians","volume":"277","author":"Deeks","year":"1997","journal-title":"JAMA"},{"key":"10.1111\/bcpt.12414-BIB0022|bcpt12414-cit-0022","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","article-title":"Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth","volume":"4","author":"Sgadari","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1111\/bcpt.12414-BIB0023|bcpt12414-cit-0023","doi-asserted-by":"crossref","first-page":"13120","DOI":"10.1073\/pnas.95.22.13120","article-title":"An inhibitor of HIV-1 protease modulates protease activity, antigen presentation and T cell responses","volume":"95","author":"Andr\u00e9","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/bcpt.12414-BIB0024|bcpt12414-cit-0024","doi-asserted-by":"crossref","first-page":"47840","DOI":"10.1074\/jbc.M105582200","article-title":"Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function","volume":"276","author":"Gruber","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/bcpt.12414-BIB0025|bcpt12414-cit-0025","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non- HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res"},{"key":"10.1111\/bcpt.12414-BIB0026|bcpt12414-cit-0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nm0302-225","article-title":"HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma","volume":"3","author":"Sgadari","year":"2002","journal-title":"Nat Med"},{"key":"10.1111\/bcpt.12414-BIB0027|bcpt12414-cit-0027","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","article-title":"HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in\u00a0vitro and in\u00a0vivo","volume":"65","author":"Gupta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1111\/bcpt.12414-BIB0028|bcpt12414-cit-0028","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/0008-5472.CAN-03-2677","article-title":"HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in\u00a0vitro and in\u00a0vivo","volume":"64","author":"Ikezoe","year":"2004","journal-title":"Cancer Res"},{"key":"10.1111\/bcpt.12414-BIB0029|bcpt12414-cit-0029","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1158\/0008-5472.CAN-06-3684","article-title":"HIV protease inhibitors enhance the efficacy of irradiation","volume":"67","author":"Cuneo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1111\/bcpt.12414-BIB0030|bcpt12414-cit-0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1535-7163.473.3.4","article-title":"HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1\/2","volume":"3","author":"Ikezoe","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/bcpt.12414-BIB0031|bcpt12414-cit-0031","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2004.05.004","article-title":"Nitric-oxide-donating NSAIDs as agents for cancer prevention","volume":"10","author":"Rigas","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1111\/bcpt.12414-BIB0032|bcpt12414-cit-0032","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00007691-200306000-00015","article-title":"Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma","volume":"25","author":"Keil","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1111\/bcpt.12414-BIB0033|bcpt12414-cit-0033","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0192-0561(97)00031-3","article-title":"Cytokine production in saquinavir treated mice","volume":"19","author":"Pacifici","year":"1997","journal-title":"Int J Immunopharmacol"},{"key":"10.1111\/bcpt.12414-BIB0034|bcpt12414-cit-0034","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1086\/515244","article-title":"Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir","volume":"177","author":"Angel","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1111\/bcpt.12414-BIB0035|bcpt12414-cit-0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1089\/088922299310368","article-title":"Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta","volume":"15","author":"Kumar","year":"1999","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1111\/bcpt.12414-BIB0036|bcpt12414-cit-0036","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1179\/joc.2001.13.4.384","article-title":"Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3\/CD28","volume":"13","author":"Comandini","year":"2001","journal-title":"J Chemother"},{"key":"10.1111\/bcpt.12414-BIB0037|bcpt12414-cit-0037","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00002030-200004140-00014","article-title":"Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects","volume":"14","author":"Tovo","year":"2000","journal-title":"AIDS"},{"key":"10.1111\/bcpt.12414-BIB0038|bcpt12414-cit-0038","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/j.atherosclerosis.2007.04.008","article-title":"Hylemon PB (2007) HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR","volume":"195","author":"Zhou","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1111\/bcpt.12414-BIB0039|bcpt12414-cit-0039","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350701200407","article-title":"Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages","volume":"12","author":"Lagathu","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1111\/bcpt.12414-BIB0040|bcpt12414-cit-0040","doi-asserted-by":"crossref","first-page":"38333","DOI":"10.1074\/jbc.M304566200","article-title":"Chronic ethanol exposure increases the binding of HuR to the TNF{alpha} 3\u2032-untranslated region in macrophages","volume":"278","author":"McMullen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/bcpt.12414-BIB0041|bcpt12414-cit-0041","doi-asserted-by":"crossref","first-page":"35734","DOI":"10.1074\/jbc.274.50.35734","article-title":"How inhibitor of the HIV-I protease modulates proteasome activity","volume":"10","author":"Schmidtke","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1111\/bcpt.12414-BIB0042|bcpt12414-cit-0042","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/00002030-200203290-00004","article-title":"The human 26S proteasome is a target of antiretroviral agents","volume":"16","author":"Piccinini","year":"2002","journal-title":"AIDS"},{"key":"10.1111\/bcpt.12414-BIB0043|bcpt12414-cit-0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3450001","article-title":"The proteasome activator 11S REG (PA28) and Class I antigen presentation","volume":"345","author":"Rechsteiner","year":"2000","journal-title":"Biochem J"},{"key":"10.1111\/bcpt.12414-BIB0044|bcpt12414-cit-0044","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","article-title":"The ubiquitin-proteasome pathway: on protein death and cell life","volume":"17","author":"Ciechanover","year":"1998","journal-title":"EMBO J"},{"key":"10.1111\/bcpt.12414-BIB0045|bcpt12414-cit-0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00002030-200401230-00005","article-title":"Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under control of c-AMP","volume":"18","author":"Johansson","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/bcpt.12414-BIB0046|bcpt12414-cit-0046","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V94.3.1021.415k29_1021_1027","article-title":"Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in\u00a0vitro and in\u00a0vivo","volume":"94","author":"Sloand","year":"1999","journal-title":"Blood"},{"key":"10.1111\/bcpt.12414-BIB0047|bcpt12414-cit-0047","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000026336","article-title":"HIV-1 tat molecular diversity and induction of TNF-alpha: implications for HIV induced neurological disease","volume":"5","author":"Mayne","year":"1998","journal-title":"NeuroImmunoModulation"},{"key":"10.1111\/bcpt.12414-BIB0048|bcpt12414-cit-0048","doi-asserted-by":"crossref","first-page":"e99144","DOI":"10.1371\/journal.pone.0099144","article-title":"Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma","volume":"9","author":"Nolen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1111\/bcpt.12414-BIB0049|bcpt12414-cit-0049","first-page":"11","article-title":"Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients","volume":"28","author":"Gazzola","year":"2013","journal-title":"J Transl Med"}],"container-title":["Basic & Clinical Pharmacology & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12414","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bcpt.12414\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T18:43:34Z","timestamp":1691606614000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,25]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"URL":"https:\/\/doi.org\/10.1111\/bcpt.12414","archive":["Portico"],"relation":{},"ISSN":["1742-7835"],"issn-type":[{"value":"1742-7835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,25]]}}}